You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

Investigational Drug Information for CORT118335


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug CORT118335?

CORT118335 is an investigational drug.

There have been 12 clinical trials for CORT118335. The most recent clinical trial was a Phase 1 trial, which was initiated on October 25th 2023.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Weight Gain. The leading clinical trial sponsors are Corcept Therapeutics, National Institute on Alcohol Abuse and Alcoholism (NIAAA), and The Scripps Research Institute.

There are five US patents protecting this investigational drug and sixty international patents.

Recent Clinical Trials for CORT118335
TitleSponsorPhase
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)Corcept TherapeuticsPhase 2
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of MiricorilantCorcept TherapeuticsPhase 1
Phase 1 Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantCorcept TherapeuticsPhase 1

See all CORT118335 clinical trials

Clinical Trial Summary for CORT118335

Top disease conditions for CORT118335
Top clinical trial sponsors for CORT118335

See all CORT118335 clinical trials

US Patents for CORT118335

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CORT118335 ⤷  Sign Up Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome Corcept Therapeutics, Inc. (Menlo Park, CA) ⤷  Sign Up
CORT118335 ⤷  Sign Up Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Corcept Therapeutics, Inc. (Menlo Park, CA) ⤷  Sign Up
CORT118335 ⤷  Sign Up Pyrimidine cyclohexyl glucocorticoid receptor modulators Corcept Therapeutics, Inc. (Menlo Park, CA) ⤷  Sign Up
CORT118335 ⤷  Sign Up Pyrimidine cyclohexyl glucocorticoid receptor modulators Corcept Therapeutics, Inc. (Menlo Park, CA) ⤷  Sign Up
CORT118335 ⤷  Sign Up Pyrimidine cyclohexyl glucocorticoid receptor modulators Corcept Therapeutics, Inc. (Menlo Park, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CORT118335

Drugname Country Document Number Estimated Expiration Related US Patent
CORT118335 Australia AU2017210156 2036-01-19 ⤷  Sign Up
CORT118335 Canada CA3011728 2036-01-19 ⤷  Sign Up
CORT118335 European Patent Office EP3405101 2036-01-19 ⤷  Sign Up
CORT118335 Spain ES2861524 2036-01-19 ⤷  Sign Up
CORT118335 Israel IL260687 2036-01-19 ⤷  Sign Up
CORT118335 Japan JP2019503495 2036-01-19 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.